These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16027417)

  • 1. Perspectives on drug withdrawals.
    Williams R
    CMAJ; 2005 Jul; 173(2):129. PubMed ID: 16027417
    [No Abstract]   [Full Text] [Related]  

  • 2. Health Canada lukewarm on Vioxx panel findings.
    Murray S
    CMAJ; 2005 Aug; 173(4):350. PubMed ID: 16103502
    [No Abstract]   [Full Text] [Related]  

  • 3. Perspectives on drug withdrawals.
    Rapoport D
    CMAJ; 2005 Jul; 173(2):128-9. PubMed ID: 16027414
    [No Abstract]   [Full Text] [Related]  

  • 4. Under surveillance.
    Nat Biotechnol; 2005 Jan; 23(1):1. PubMed ID: 15637596
    [No Abstract]   [Full Text] [Related]  

  • 5. Rofecoxib, Merck, and the FDA.
    Villalba L; Witter J
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
    [No Abstract]   [Full Text] [Related]  

  • 6. Balancing the cyclooxygenase portfolio.
    Armstrong PW
    CMAJ; 2006 May; 174(11):1581-2. PubMed ID: 16717266
    [No Abstract]   [Full Text] [Related]  

  • 7. Agencies "failed miserably" over COX-2 inhibitor.
    Kermode-Scott B
    BMJ; 2005 Jan; 330(7483):113. PubMed ID: 15649923
    [No Abstract]   [Full Text] [Related]  

  • 8. Keeping science on top in drug evaluation.
    Avorn J
    N Engl J Med; 2007 Aug; 357(7):633-5. PubMed ID: 17699813
    [No Abstract]   [Full Text] [Related]  

  • 9. [Cardiovascular risk: a class effect of coxibs? How to manage patients taking Vioxx?].
    Brune K; Zacher J
    MMW Fortschr Med; 2004 Oct; 146(42):10, 12. PubMed ID: 15536697
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cyclooxygenase-2 inhibitors and the ethics of research].
    Gherardi CR
    Medicina (B Aires); 2005; 65(5):476. PubMed ID: 16296649
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug safety special: the safety catch.
    Wadman M
    Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591
    [No Abstract]   [Full Text] [Related]  

  • 12. [Overestimated].
    Höer A; Häussler B
    Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
    [No Abstract]   [Full Text] [Related]  

  • 13. Crossing the line: part 2.
    Blaivas JG
    Neurourol Urodyn; 2005; 24(1):1. PubMed ID: 15593361
    [No Abstract]   [Full Text] [Related]  

  • 14. What ails the FDA?
    Gorelick KJ
    N Engl J Med; 2005 Jun; 352(24):2553-4. PubMed ID: 15958814
    [No Abstract]   [Full Text] [Related]  

  • 15. The Vioxx debacle.
    Alpert JS
    Am J Med; 2005 Mar; 118(3):203-4. PubMed ID: 15745713
    [No Abstract]   [Full Text] [Related]  

  • 16. The Vioxx debacle revisited.
    Manthous CA
    Am J Med; 2005 Sep; 118(9):1056-7; author reply 1057. PubMed ID: 16164904
    [No Abstract]   [Full Text] [Related]  

  • 17. The Vioxx debacle revisited.
    Mohapatra PR; Janmeja AK
    Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909
    [No Abstract]   [Full Text] [Related]  

  • 18. Causation, Vioxx, and legal issues.
    Green MD
    Science; 2005 Nov; 310(5750):973. PubMed ID: 16284163
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety, scrutiny and conflicts: assessing the fallout and lessons learned from pharmaceuticals.
    Lanzafame RJ
    Photomed Laser Surg; 2005 Feb; 23(1):1-2. PubMed ID: 15782023
    [No Abstract]   [Full Text] [Related]  

  • 20. What happened to the coxibs on the way to the cardiologist?
    Alberts DS; Potter JD; Martinez ME; Hess LM; Stopeck A; Lance P
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):555-6. PubMed ID: 15767326
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.